Zoetis Inc (ZTS)

Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTSJune 8, 2026 2:35 AM
PR Newswire (US) LOS ANGELES, June 8, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zoetis Inc. ("Zoetis" or "the Company") (NYSE: ZTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of ZTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: January 14, 2025 to May 6, 2026DEADLINE: July 27, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Zoetis faced challenges in multiple product lines including Librela, Apoquel, and Cytopoint. Based on these facts, Zoetis' public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com View original content:https://www.prnewswire.com/news-releases/zoetis-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--zts-302793623.htmlSOURCE DJS Law Group LLP Original: Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTS

ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallStJune 4, 2026 5:33 PM
PR Newswire (US) Time-Sensitive: Allegations Focus on Concealed FDA Safety Warnings and Competitive Market Share Erosion That Cost ZTS Investors BillionsNEW YORK, June 4, 2026 /PRNewswire/ -- SueWallSt alerts investors in Zoetis Inc. (NYSE: ZTS) of a pending securities class action. Class Period: January 14, 2025 through May 6, 2026. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com | (888) SueWallSt. Zoetis shares collapsed 21.5%, a loss of nearly $24 per share, as the market learned the Company's Companion Animal franchise was under far greater pressure than management disclosed. The Court has set July 27, 2026 as the deadline to apply for lead plaintiff appointment.The Alleged FDA Safety Concealment and Its Market ConsequencesIn December 2024, the FDA issued a "Dear Veterinarian" letter describing severe adverse neurological events in dogs treated with Librela, including seizures, paresis, recumbency, and death. The lawsuit asserts that management minimized the letter's significance to investors, characterizing it as "terribly helpful" and "consistent with what we've been telling them." In reality, the action claims, veterinarian confidence in prescribing Librela was deteriorating sharply, directly undermining the growth trajectory management promoted.A label update warning of neurological and mobility-related events was subsequently applied to Librela. Rather than disclose the prescribing slowdown this triggered, the Company allegedly continued to tout "very strong satisfaction levels" and "record penetration" among clinics.Elanco's Competitive Threat and the Dermatology and Parasiticide ErosionThe lawsuit contends that management concealed the pace at which Elanco's newly launched therapies were capturing market share:Elanco's Zenrelia, launched in late 2024, was marketed as comparable or superior to Apoquel at a lower price, directly threatening Zoetis' dermatology dominanceElanco's Credelio Quattro offered tapeworm coverage Simparica Trio lacked and was priced below Trio, accelerating competitive switchingManagement repeatedly claimed competitors were having "very limited impact" and that Trio had "not experienced year-over-year patient share loss"By May 2026, the Company admitted "share loss is being amplified by a derm market with declining patient volume in the clinic"The $2.5 billion dermatology TAM projection (11% CAGR) that underpinned Zoetis' premium valuation was built on market leadership claims that were allegedly crumblingWhy Alleged Concealment of Competitive Dynamics Matters to ZTS InvestorsAs alleged in the action, Zoetis portrayed its Companion Animal segment as insulated from competitive threats through "first mover advantage," "strong commercial relationships," and "customer loyalty." These representations allegedly masked a reality where lower-priced rivals with broader label claims were systematically eroding prescription volumes, veterinarian preference, and pricing power across all three major franchises simultaneously.The lawsuit claims that when management finally acknowledged on May 7, 2026 that "competition intensified across key pet care categories" and "pet owners demonstrated increased price sensitivity," the stock lost 21.5% in a single session."Investors deserve transparency about material risks that could affect their investments. When a company faces intensifying competition and regulatory headwinds that threaten its core revenue streams, shareholders are entitled to know." -- Joseph E. Levi, Esq.Speak with an attorney about recovering damages or call (888) SueWallSt.WHY SUEWALLST -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, SueWallSt is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.Frequently Asked Questions About the ZTS LawsuitQ: Who is eligible to join the ZTS investor lawsuit? A: Investors who purchased ZTS stock or securities between January 14, 2025 and May 6, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.Q: What specific misstatements does the ZTS lawsuit allege? A: The complaint alleges Zoetis made materially false or misleading statements regarding the competitive strength of its Companion Animal franchise, the impact of FDA safety warnings on Librela prescribing trends, and the degree to which Elanco's new products were capturing market share from Simparica Trio and Apoquel/Cytopoint. When the true state was revealed, the stock price declined sharply.Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.Q: What is the ZTS lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is July 27, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.Q: What if I already sold my ZTS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.CONTACT:
SueWallSt
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi @Icons1 View original content to download multimedia:https://www.prnewswire.com/news-releases/zts-shareholder-alert-zoetis-inc-securities-class-action-lawsuit---investors-should-contact-suewallst-302791953.htmlSOURCE SueWallSt.com Original: ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTSJune 3, 2026 2:57 AM
PR Newswire (US) LOS ANGELES, June 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zoetis Inc. ("Zoetis" or "the Company") (NYSE: ZTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of ZTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: January 14, 2025 to May 6, 2026DEADLINE: July 27, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Zoetis faced challenges in multiple product lines including Librela, Apoquel, and Cytopoint. Based on these facts, Zoetis' public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com View original content:https://www.prnewswire.com/news-releases/zoetis-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--zts-302789505.htmlSOURCE DJS Law Group LLP Original: Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTS

Zoetis Declares Third Quarter 2026 DividendMay 20, 2026 4:15 PM
Business Wire The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the third quarter of 2026. The dividend will be paid on Tuesday, September 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Monday, July 20, 2026. About Zoetis Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com. DISCLOSURE NOTICES Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis. ZTS-COR
ZTS-IR
ZTS-FIN View source version on businesswire.com: https://www.businesswire.com/news/home/20260519062480/en/ Media Contacts:
Jennifer Albano
1-862-399-0810 (o)
jennifer.albano @stock picker-975-5176 (o)
laura.panza@zoetis.com Investor Contacts:
Steve Frank
1-973-822-7141 (o)
steve.frank @stock picker-443-2792 (o)
nick.soonthornchai@zoetis.com Original: Zoetis Declares Third Quarter 2026 Dividend

Zoetis shares slip after announcing $160M acquisition of Neogen genomics unitMarch 2, 2026 11:14 AM
IH Market News
Shares of Zoetis Inc (NYSE:ZTS) edged 1.1% lower to $129.72 in premarket trading on Monday after the animal health company revealed plans to acquire the animal genomics division of Neogen Corporation (NASDAQ:NEOG) in a deal valued at $160 million.The transaction will give Zoetis access to Neogen’s genetic testing capabilities and data analytics platforms, which the company intends to use to enhance disease prediction and enable more tailored healthcare solutions for animals.Neogen’s genomics business operates five laboratories located in the United States, Brazil, Australia, China and the United Kingdom, along with an additional office in Canada, serving customers across more than 120 countries worldwide.Zoetis said the acquisition is expected to close during the second half of calendar year 2026, subject to customary conditions.The company’s shares had gained approximately 4.2% during 2025 prior to Monday’s decline.Zoetis stock price

Original: Zoetis shares slip after announcing $160M acquisition of Neogen genomics unit

This may be the first one you are correct on

🚨 VACCINES AND PET CANCER? DR. JUDY JASEK RAISES THE ALARM 🚨

🔴 “We’re seeing cancer in younger and younger pets — and nobody’s asking why.”
🗣️ Holistic veterinarian Dr. Judy Jasek is sounding the alarm:
Toxicity in pet vaccines may be triggering a cancer epidemic in our… pic.twitter.com/eFPgmDPvZC— Jim Ferguson (@JimFergusonUK) April 25, 2025 $ZTS

Veterinarians across the country are currently injecting experimental self-amplifying RNA shots into our dogs and cats: Nobivac NXT by Merck

These injections are currently widely available for online purchase.

The so-called “safety” data for these injections is as follows:… https://t.co/RHYlOkRYyx pic.twitter.com/Hdd87jCShf— Nicolas Hulscher, MPH (@NicHulscher) April 25, 2025 $ZTS

My question then is. this is basically the same as any pharma company out there. When a new drug comes along that's innovative, the stock rockets. So why no rocketing?

$PETV The studies will show dramatic benefits to the dogs, the same as horses. The granulated matrix of heparin, collagen and elastin when injected becomes sponge-like creating a lubricated environment. It also seals the synovial sac and helps the body rebuild the joint. Very different than blocking the nerve as Librela does. It solves the problem! This is why it will take over Librela’s sales!

As a PetVivo salesman, I’d like to discuss why Spryng is a superior choice for treating osteoarthritis in dogs and cats compared to Librela. Let’s examine the facts: Librela’s Concerning Safety Profile Librela, while marketed as an effective treatment, comes with significant risks: • The FDA received over 3,800 reports of side effects through the end of 2023 • The European Medicines Agency received more than 12,300 adverse event reports since 2021 These side effects include: • Ataxia • Seizures • Neurological issues (paresis, recumbency) • Urinary incontinence • Polyuria and polydipsia • In some cases, death or euthanasia Just three weeks ago, the FDA cited Zoetis for potentially underreporting more severe side effects, raising serious concerns about the drug’s safety profile. Problems with Nerve Growth Factor Inhibition Librela’s mechanism of action, inhibiting nerve growth factor (NGF), can lead to: • Increased risk of rapidly progressive osteoarthritis • Potential for osteonecrosis • Systemic effects throughout the body, not just in affected joints • Dramatic increase in systemic oxidative stress, particularly harmful for animals in pre-arthritis and early arthritis stages Spryng: A Superior Alternative Now, let me introduce you to Spryng, a revolutionary treatment that addresses the root cause of osteoarthritis: 1. Mechanism of Action: • Provides a shock-absorbing matrix that mimics natural cartilage • Directly addresses joint mechanics, not just masking pain 2. Safety Profile: • Demonstrated excellent safety in clinical studies • No significant adverse events reported • Localized to the injected joint, minimizing systemic effects 3. Long-lasting Effects: • A single injection can provide benefits for up to 12 months or longer • Compared to Librela’s required monthly injections 4. Cost-effective: • Approximately 50% cheaper for the customer over the course of a year 5. Natural Composition: • Made from purified, naturally-derived proteins and carbohydrates • Mimics the structure and function of natural cartilage 6. Regulatory Advantage: • Classified as a veterinary medical device, not requiring FDA premarket approval 7. Versatility: • Effective for all stages of osteoarthritis • Can be used in multiple joint locations By choosing Spryng, you’re offering your patients a safer, more effective, and cost-efficient solution for managing osteoarthritis. It’s time to move beyond simply masking pain and address the underlying cause of joint issues, providing long-term relief and improved quality of life for our furry companions.

Investment Pitch: PetVivo Holdings (PETV) - A Promising Opportunity in the Canine Arthritis
Treatment Market Market Overview The canine arthritis treatment market is experiencing
significant growth, with Zoetis Inc. (ZTS) leading the way with its Librela product. However,
recent developments have created an opportunity for PetVivo Holdings (PETV) to capture
market share with its innovative Spryng
™
treatment. Zoetis’s Librela: Market Leader Facing
Challenges Librela, Zoetis’s flagship product for canine osteoarthritis, has achieved
remarkable success:

• $400 million in global canine market sales for 2024 • 90% contribution margins, adding
$360 million to ZTS earnings (approximately 15%)

• Monthly injection priced at $160 retail However, Librela is now facing significant
headwinds: • FDA warning issued to veterinarians about serious adverse events in dogs
treated with Librela • Reported side effects include ataxia, seizures, impaired muscle
function, and in some cases, death

• This FDA response typically causes hesitation among veterinarians in prescribing the
medication PetVivo’s Spryng
™
: A Promising Alternative PetVivo’s Spryng
™ with
OsteoCushion
™
Technology offers several advantages: • Once-per-year injection priced at
$600, potentially more cost-effective for pet owners

• FDA
-approved veterinary medical device, not a drug, offering pain moderation without
pharmacologic action

• No reported serious side effects

• Natural, viscosolid matrices that mimic cartilage properties • Long-lasting joint benefits
from a single treatment

• Can be used in multiple joints as part of the same treatment Market Opportunity for
PetVivo

1. Established Distribution: MWI, a division of AmerisourceBergen, the largest drug
distributor, markets PetVivo’s Spryng product

2. Market Reach: PetVivo has reached all small animal vets over the past 2 years,
positioning it to capitalize on Librela’s challenges

3. Competitive Advantage: Spryng is the only naturally derived cartilage reinforcement
product for veterinary use

4. Growth Potential: With Zoetis facing regulatory challenges, PetVivo is well-positioned to
capture market share

5. Valuation Disparity: • Zoetis: $73 billion market cap • PetVivo: $12 million market cap
Investment Thesis 3. Untapped Potential: PetVivo’s small market cap compared to Zoetis
suggests significant room for growth 2. Product Superiority: Spryng’s natural composition
and less frequent dosing may appeal to pet owners and veterinarians concerned about
Librela’s side effects 3. Market Disruption Opportunity: FDA warnings about Librela create
an opening for alternative treatments like Spryng 4. Established Infrastructure: PetVivo’s
existing relationships with veterinarians and partnership with a major distributor provide a
solid foundation for rapid market penetration 5. Regulatory Advantage: As a medical
device, Spryng may face less scrutiny than drug-based treatments Risks to Consider •
Competition from other major players like Merck Animal Health • Potential for Zoetis to
address FDA concerns and maintain market dominance • Execution risks associated with
scaling up production and sales Conclusion PetVivo Holdings (PETV) represents a
compelling investment opportunity in the canine arthritis treatment market. With its
innovative Spryng
™
product, established distribution channels, and the current challenges
facing the market leader, PetVivo is well-positioned to capture significant market share and
potentially deliver substantial returns to investors.

imo....pipe up and say one thing on this board and we will ruin your whole day....ZTS

ZTS


IHuser

imo.. might go for a boat ride and torture your own dog or something...jmo ZTS

IHuser

Just broke the support line and all my profits got away this time. Guess I'll look to re-enter later

imo.. might want to sell cuz I got the whole world following me~

ZTS

IHuser

The "yacht" was great. Took the family to the Galapagos. Not what I expected but off the bucket list.
I'm not going back to Ecuador anytime soon.
There are many companies these days that make no sense, starting with Twitter.
Wrestling cobras isn't on my bucket list.

imo...seen your boat you rented....wih ZTS naive gullible little bulls money~ btw my dog gets covid 19 all the time when he wrestles cobra snakes...ust sayin'


ZTS

IHuser

Humans roamed without medicines as well.

imo... animals have roamed the Earth without meddling humans for twenty years....one time....i remember...i was there~ ZTS



IHuser

What's your point? Medicines shouldn't be used?

imo...my dog that followed me home lived to 15 without these evil mf's......and my cats.....ZTS


IHuser

imo... F You........we are coming for you bud.......


ZTS

IHuser

imo....ZTS we have landed





IHuser

Time to vaccinate your cats and dogs for Covid-19.
Zoetis creator of Covid-19 Vaccine for animals.
The Detroit Zoo in Michigan has launched a drive to vaccinate its animals against Covid-19, using a specially designed shot to immunize gorillas, lions, chimpanzees and other critters thought to be most susceptible to the virus.

Joining more than 5 million fully vaccinated Michiganders – humans, that is – some animals at the Detroit Zoo are now being inoculated with a special vaccine created for veterinary use, the Detroit Zoological Society (DZS) announced in a statement on Monday.

“Much like we vaccinate dogs for things like parvovirus, distemper or rabies, this is needed to protect animals at the Zoo,” said Dr. Ann Duncan, director of animal health for the DZS.
Detroit Zoo's most susceptible animals are getting COVID-19 vaccinations

Detroit Zoo's most susceptible animals are getting COVID-19 vaccinations
freep.com
Developed by Zoetis – a pharma firm whose research team is based in Kalamazoo, Michigan – the animal-specific vaccine was first administered to gorillas, chimpanzees, tigers and lions at the Detroit facility. While the zoo said none of its animals have yet contracted the illness, it noted that cases have been detected at other American zoos, and that a tiger and a lion had died from the virus at facilities in India and Europe, suggesting risk of infection does exist for many animals.

“We’re both thankful and relieved a special vaccine is now available to protect against Covid-19,” Scott Carter, chief life sciences officer for the zoological society, added.

Many of the mammals are trained to present themselves to our animal care staff for minor medical procedures, including vaccinations.

Eight lions contract Covid-19 at Hyderabad zoo amid coronavirus surge in India

The Zoetis jab was first unveiled earlier this year at a zoo in San Diego, California, where four orangutans and five bonobos became the first non-human primates to be vaccinated against the virus. Eight gorillas at the same zoo had previously tested positive for the virus – reportedly the first of their species to do so – but were not vaccinated as they were thought to have developed natural immunity. 

Though the company originally developed the formulation for dogs and cats, it appears to have worked as intended in other animals and has triggered no adverse reactions. 

Zoetis is not the only pharma firm looking to produce jabs for other creatures, however, with the Russian-developed Carnivac-Cov vaccine officially registered by the country’s regulators last March. Touted by its creators as “the first, and to date, the only Covid-19 product in the world for animals,” the vaccine was proven effective for dogs, cats, arctic foxes and minks, among others.

???????????????

$ZTS Bearish $10.00 coming

New talk on human drug development by veterinary trials for novel pain therapies BY Steven Kamerling, Therapeutic Area Head for Pain, Inflammation and Oncology at Zoetis. Details on the talk this May at Pain Therapeutics 2017 are available at http://www.pain-therapeutics.co.uk/ihub

Agree... fundamental analysis implies Zoetis $ZTS is 17% overvalued before earnings Thursday:

Fair Value Source

Looks like a good short opportunity here. Will start a small position if it pushes a little higher with stop above aug high

Dr Mahesh Kumar, VP of Global Biological Research & Development at Zoetis will be presenting an interesting keynote address entitled "First to know and fast to market!" at the Superbugs USA congress. Details are available at http://www.superbugs-usa.com/ihub

Looks to be back on the move.....finally.

Nice 3 day run here. Go ZTS

Nice day

VRX in pursuit of ZTS, says WSJ: #msg-114927831.

Nice pick

This looks interesting.

Better late than never—slide deck from ZTS’ Nov2014 Investor Day:

https://zoetis.investorhq.businesswire.com/sites/zoetis.investorhq.businesswire.com/files/doc_library/file/Zoetis_Investor_Day_2014_111814.pdf

$ZTS DD Notes ~ http://www.ddnotesmaker.com/ZTS

bullish

$ZTS recent news/filings

## source: finance.yahoo.com

Wed, 17 Dec 2014 22:55:48 GMT ~ Zoetis Boosts Dividend After Ackman Raises Stake


read full: http://www.bloomberg.com/news/2014-12-17/zoetis-boosts-dividend-after-ackman-raises-stake.html?cmpid=yhoo
*********************************************************

Wed, 17 Dec 2014 21:27:41 GMT ~ Zoetis raises quarterly dividend 15%


read full: http://www.marketwatch.com/News/Story/Story.aspx?guid=6BFBC7A0-916C-4240-9167-07001708F373&siteid=yhoof2
*********************************************************

Wed, 17 Dec 2014 21:18:50 GMT ~ ZOETIS INC. Files SEC form 8-K, Regulation FD Disclosure


read full: http://biz.yahoo.com/e/141217/zts8-k.html
*********************************************************

Wed, 17 Dec 2014 21:15:00 GMT ~ Zoetis Declares First Quarter 2015 Dividend; Board Approves 15% Payment Increase

[Business Wire] - The Board of Directors of Zoetis Inc. has declared a first quarter 2015 dividend payable to holders of the company’s common stock of $0.083 per share, an increase of 15% from the quarterly dividend rate paid in 2014.

read full: http://finance.yahoo.com/news/zoetis-declares-first-quarter-2015-211500638.html
*********************************************************

Wed, 17 Dec 2014 13:29:00 GMT ~ Zoetis to Participate in the 33rd Annual J.P. Morgan Healthcare Conference

[Business Wire] - Zoetis Inc. will participate in the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 14, in San Francisco, Calif. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts.

read full: http://finance.yahoo.com/news/zoetis-participate-33rd-annual-j-132900016.html
*********************************************************


$ZTS charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$ZTS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ZTS/company-info
Ticker: $ZTS
OTC Market Place: Not Available
CIK code: not found
Company name: Zoetis Inc.
Incorporated In:


$ZTS share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$ZTS extra dd links

Company name: Zoetis Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ZTS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ZTS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ZTS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/news - http://finance.yahoo.com/q/h?s=ZTS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ZTS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ZTS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ZTS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Zoetis+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Zoetis+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Zoetis+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ZTS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ZTS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ZTS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ZTS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ZTS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ZTS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ZTS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ZTS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ZTS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ZTS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ZTS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ZTS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ZTS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ZTS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ZTS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ZTS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ZTS



$ZTS DD Notes ~ http://www.ddnotesmaker.com/ZTS

$ZTS DD Notes ~ http://www.ddnotesmaker.com/ZTS

bullish

$ZTS recent news/filings

## source: finance.yahoo.com

Wed, 03 Dec 2014 16:32:01 GMT ~ Zoetis in a Growing Global Animal Health Industry


read full: http://finance.yahoo.com/news/zoetis-growing-global-animal-health-163201790.html
*********************************************************

Tue, 02 Dec 2014 13:29:00 GMT ~ Zoetis to Participate in the Bank of America Animal & Dental Health Summit

[Business Wire] - Zoetis Inc. will participate in the Bank of America Animal & Dental Health Summit on Thursday, Dec. 11, in Boston, Mass. Paul Herendeen, Executive Vice President and Chief Financial Officer, and Clint Lewis, Executive Vice President and President, U.S.

read full: http://finance.yahoo.com/news/zoetis-participate-bank-america-animal-132900049.html
*********************************************************

Wed, 26 Nov 2014 14:03:43 GMT ~ Jefferies Raises Zoetis Price Target, Says Consolidation Continues To Look Likely


read full: http://finance.yahoo.com/news/jefferies-raises-zoetis-price-target-140343487.html
*********************************************************

Mon, 24 Nov 2014 23:29:04 GMT ~ Bayer explores possible sale of diabetes device unit -Bloomberg


read full: http://uk.finance.yahoo.com/news/bayer-explores-possible-sale-diabetes-232904416.html
*********************************************************

Mon, 24 Nov 2014 14:00:00 GMT ~ Zoetis Announces Appointment of Roman Trawicki as President of Global Manufacturing and Supply

[Business Wire] - Zoetis Inc. today announced the appointment of Roman Trawicki as President of its Global Manufacturing and Supply organization.

read full: http://finance.yahoo.com/news/zoetis-announces-appointment-roman-trawicki-140000089.html
*********************************************************


$ZTS charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$ZTS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ZTS/company-info
Ticker: $ZTS
OTC Market Place: Not Available
CIK code: not found
Company name: Zoetis Inc.
Incorporated In:


$ZTS share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$ZTS extra dd links

Company name: Zoetis Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ZTS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ZTS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ZTS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/news - http://finance.yahoo.com/q/h?s=ZTS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ZTS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ZTS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ZTS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Zoetis+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Zoetis+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Zoetis+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ZTS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ZTS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ZTS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ZTS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ZTS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ZTS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ZTS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ZTS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ZTS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ZTS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ZTS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ZTS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ZTS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ZTS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ZTS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ZTS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ZTS



$ZTS DD Notes ~ http://www.ddnotesmaker.com/ZTS

Go ZTS , Had to jump in since they fixed my dog. Proven product to me.

ZTS Zoetis trading halted, pending news :theflyonthewall.com

Cool. I buy what Bill buys.
Follow the money.

ZTS buys ABT’s animal-health business for $255M in cash:

http://finance.yahoo.com/news/zoetis-purchase-assets-abbott-animal-131500944.html

As is obvious from the price, animal-health was a very small part of ABT’s overall business.

Big bad Ackman owns 41,000,000 shares.

In at 42.64

SMART MONEY NOW ZTS!!

IF YOU LOVE YOUR DOG...YOU WILL BUY ZTS NOW!

DOGS LOVE ZTS ZTS SAVED MANY DOGS AND OTHER ANIMALS..ZTS STRONG BUY

ZTS Zoetis Inc, is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The primary livestock species are cattle (both beef and dairy), swine, poultry, sheep and fish, and the primary companion animal species are dogs, cats and horses. The Company’s more than 300 product lines include vaccines, parasiticides, anti-infectives, medicated feed additives and other pharmaceutical products. The Company’s product portfolio also includes businesses, such as diagnostics, genetics, devices and services, such as dairy data management, e-learning and professional consulting. The Company operates in North America, Europe, Africa, Asia, Australia and Latin America.